Patients with cancer run a high risk of recurrent VTE and bleeding. Although major guidelines recommend low-molecular-weight heparin and have recently added edoxaban and rivaroxaban, the high risk of bleeding (mainly at GI sites) poses a serious issue and limits the clinical benefit of these drugs. The CARAVAGGIO trial, presented by Prof. Giancarlo Agnelli (University of Perugia, Italy), assessed whether oral apixaban (10 mg twice daily for the first 7 days, 5 mg twice daily thereafter) was non-inferior to subcutaneous dalteparin (200 IU/kg once daily for the first month and then 150 IU/kg once daily) in the treatment of proximal deep-vein thromboembolism (DVT) and/or pulmonary embolism (PE) in patients suffering from cancer.
The study was conducted in Europe, Israel, and the United States and enrolled 1,170 patients with cancer who had newly diagnosed, objectively confirmed symptomatic or incidental proximal lower-limb DVT, or symptomatic or incidental PE in a segmental or more proximal pulmonary artery. The primary endpoint was recurrent proximal DVT or PE over 6 months, as assessed by a central, independent adjudication committee unaware of study treatment allocation. The primary safety outcome was major bleeding defined according to the guidelines of the International Society of Thrombosis and Haemostasis (ISTH). Patients were randomised to apixaban (n=585) or dalteparin (n=585). Baseline characteristics were comparable between both groups. The most common type of cancer was colorectal cancer, followed by lung cancer, and breast cancer.
Recurrent VTE occurred in 5.6% of apixaban patients and 7.9% of dalteparin patients (HR 0.63; 95% CI 0.37-1.07; P<0.001 for non-inferiority and P=0.08 for superiority, see Table). This was 2.3% and 2.6% for recurrent DVT, and 3.3% and 5.5% for PE, respectively. Fatal PE occurred in 0.7% and 0.5% of patients, respectively. The primary safety endpoint of major bleeding was observed in 3.8% of patients on apixaban and 4.0% of patients on dalteparin (HR 0.82; 95% CI 0.40-1.69; P=0.60). Major GI bleeding occurred in 1.9% and 1.7% of patients, respectively. In conclusion, the CARAVAGGIO study provided compelling evidence that while apixaban could provide comparable protection from recurrence of VTE as compared with low-molecular-weight heparin, no substantial increase in bleeding hazard was observed.
Table: Primary efficacy outcomes of the CARAVAGGIO trial [1]

CI, confidence interval; DVT, deep-vein thromboembolism; PE, pulmonary embolism; VTE, venous thromboembolism.
- Agnelli G, et al. Abstract 406-09. ACC/WCC 28-30 March 2020.
- Agnelli G, et al. N Engl J Med. 2020; DOI: 10.1056/NEJMoa1915103.
Posted on
Previous Article
« Rivaroxaban superior to enoxaparin in preventing VTE in non-major orthopaedic surgery Next Article
Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel »
« Rivaroxaban superior to enoxaparin in preventing VTE in non-major orthopaedic surgery Next Article
Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel »
Table of Contents: ACC/WCC 2020
Featured articles
Heart Failure and Cardiomyopathies
Mavacamten shows promising results in non-obstructive hypertrophic cardiomyopathy
Vericiguat shows beneficial effects in a very high-risk HF population
No role for sodium nitrite in out-of-hospital cardiac arrest
Vascular Medicine and Thromboembolism
Rivaroxaban and aspirin effective and safe for PAD patients
TAILOR-PCI misses endpoint but still provides valuable insights
Edoxaban: alternative to warfarin after surgical aortic or mitral valve procedures?
Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel
Apixaban offers new perspective for cancer patients in need of anticoagulation
Rivaroxaban superior to enoxaparin in preventing VTE in non-major orthopaedic surgery
Interventional Cardiology
TAVR safe and effective in low-risk bicuspid aortic stenosis patients
TAVR model reveals differences in hospital outcomes
2-year results show non-significant outcomes TAVR vs surgery in severe aortic stenosis
Renal denervation better than sham for blood pressure
Infusion of ethanol in the vein of Marshall for persistent AF
Atrial Fibrillation/Acute Coronary Syndrome
Fewer adverse events with ticagrelor monotherapy after 3 months DAPT
TWILIGHT sub-study: same outcomes for diabetes patients
TWILIGHT sub-study: complex PCI patients
LAAO Watchman registry data positive
Apixaban in AF patients with recent ACS/PCI: Drop aspirin after 30 days
Genetics and Prevention
Homozygous FH responds to alirocumab
Evinacumab significantly reduces LDL-C in homozygous FH patients
Higher serum levels of eicosapentaenoic acid correlate with reduced CV events
Quit smoking: vaping + counselling helps
Related Articles
September 8, 2020
LAAO Watchman registry data positive

September 7, 2020
Rivaroxaban and aspirin effective and safe for PAD patients
September 7, 2020
Subgroup analysis VOYAGER PAD
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com